
Publication|Articles|March 30, 2026
- ONCOLOGY Vol 40, Issue 2
- Volume 40
- Issue 02
- Pages: 74-79
Lifesaving Upgrades: Reviewing 40 Years of FDA Oncology Approvals
Author(s)Tim Cortese
ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.
Advertisement
Advertisement
Over the past 40 years, hundreds of drugs have been approved across a multitude of cancer types. With numbers so great, it is guaranteed that some will fall to the wayside and be forgotten while others will persist throughout decades, affecting treatment paradigms even 30 years down the line. In celebration of the journal ONCOLOGY’s 40th anniversary, it was only fitting to document prominent FDA oncology approvals, starting from 1986 and ending in 2026.
Related to this article

Neoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.

National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.

The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.

Rezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.

Anne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.

The FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.

Variation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture.
Advertisement
Advertisement

